Zagociguat - Cyclerion Therapeutics
Alternative Names: CY-6463; IW-6463Latest Information Update: 13 May 2025
At a glance
- Originator Ironwood Pharmaceuticals
- Developer Cyclerion Therapeutics; Tisento Therapeutics
- Class Antidementias; Antipsychotics; Nootropics; Small molecules
- Mechanism of Action Soluble guanylyl cyclase agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; MELAS syndrome; Mitochondrial disorders
- No development reported Dementia; Schizophrenia
Most Recent Events
- 06 May 2025 Tisento Therapeutics plans a phase II PRIZM trial for MELAS syndrome (PO, Tablet) in August 2025 (NCT06961344)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Schizophrenia(Treatment-experienced) in USA (PO, Tablet)
- 10 Sep 2024 Phase-II clinical trials in MELAS syndrome in Germany, Australia, USA (PO) (NCT06402123)